Application of novel gamma delta T cell to preparation of kit for evaluating curative effect of AML (acute myeloid leukemia)

Abstract

The invention provides application of a novel gamma delta T cell subpopulation to preparation of a kit for predicting the curative effect and prognosis of AML (acute myeloid leukemia). The inventor based on the invention discovers the expression condition of the novel gamma delta T cell subpopulation in peripheral blood of patients suffering from AML is associated with the curative effect and theprognosis of the patients suffering from AML for the first time. When the expression ratio of the novel PD1+Foxp3+gamma delta T cell subpopulation is high, the possibility of bad clinical curative effect of the patients suffering from AML is high. The expression ratio of the novel gamma delta T cell subpopulation has important guide significance in prognosis judgment of the patients suffering fromAML and formulation of a clinical treatment scheme. More base research data can be provided for individual treatment of the patients suffering from AML, and wide application prospect in clinical curative effect and prognosis evaluation of the patients suffering from AML is achieved.

Description

technical field [0001] The invention belongs to the field of biomedicine, and particularly relates to the application of novel γδT cell subsets in the preparation of a kit for predicting the curative effect and prognosis of AML. Background technique [0002] Acute myeloid leukemia (AML) is a group of malignant clonal diseases originating from hematopoietic stem cells with high heterogeneity. Leukemic cells stagnate at different stages of cell development due to the loss of the ability to differentiate and mature, and develop in the bone marrow. It is the most common type of leukemia in adults. At present, the treatment of AML mainly includes induction therapy and consolidation therapy. In the past 30 years, although the treatment of AML has achieved certain curative effect, for some AML patients with adverse chromosomal or gene abnormal changes, the leukemia cells in the body cannot be completely eliminated. Still facing relapse or drug resistance after remission. At prese...

AI Technical Summary

Problems solved by technology

At present, the treatment of AML mainly includes induction therapy and consolidation therapy. In the past 30 years, although the treatment of AML has achieved certain curative effect, for some AML patients with adverse chromosomal or gene abnormal changes, the leukemia cells in the body cannot be completely eliminated. Still facing post-remission relapse or drug resistance

At present, there is no effective treatment for refractory and relapsed AML patients, so new treatment strategies need to be further proposed to remove the minimal residual lesions, prolong the life of patients, and improve their quality of life

At present, there are no laboratory indicators related to γδT cell subsets that can effectively predict the clinical efficacy and state evaluation of AML patients; there is no research in the industry on whether the PD-1 signaling pathway is involved in the regulation of γδTreg cells in AML patients

Images